New York State Common Retirement Fund boosted its holdings in Angion Biomedica Corp. (NASDAQ:ANGN) by 98.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,746 shares of the company’s stock after purchasing an additional 2,846 shares during the quarter. New York State Common Retirement Fund’s holdings in Angion Biomedica were worth $75,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of ANGN. Park West Asset Management LLC acquired a new stake in Angion Biomedica in the 1st quarter valued at $17,001,000. BVF Inc. IL acquired a new stake in Angion Biomedica in the 1st quarter valued at $15,811,000. Franklin Resources Inc. acquired a new stake in Angion Biomedica in the 1st quarter valued at $11,113,000. BlackRock Inc. purchased a new position in Angion Biomedica during the 1st quarter worth $5,670,000. Finally, JPMorgan Chase & Co. purchased a new position in Angion Biomedica during the 1st quarter worth $3,244,000. 16.88% of the stock is owned by institutional investors and hedge funds.
A number of research firms have issued reports on ANGN. Zacks Investment Research raised shares of Angion Biomedica from a “sell” rating to a “hold” rating in a report on Tuesday, August 3rd. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of Angion Biomedica in a report on Monday, September 13th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Angion Biomedica has a consensus rating of “Buy” and a consensus target price of $59.33.
Angion Biomedica (NASDAQ:ANGN) last released its earnings results on Wednesday, August 11th. The company reported ($0.58) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.69) by $0.11. Equities research analysts forecast that Angion Biomedica Corp. will post -3.42 earnings per share for the current fiscal year.
Angion Biomedica Profile
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3777, a hepatocyte growth factor mimetic for acute kidney injury, acute lung injury, acute respiratory distress syndrome, central nervous system injuries, and heart injuries.
Featured Article: Risk Tolerance and Your Investment Decisions
Receive News & Ratings for Angion Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Angion Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.